Metastatic gastric cancer - focus on targeted therapies

Biologics: Targets and Therapy

Volumn 6, Issue , 2012, Pages 137-146

  Meza Junco, Judith ^a   Sawyer, Michael B ^a  

^a CROSS CANCER INSTITUTE   (Canada)

Author keywords

Anti EGFR drugs; Antiangiogenesis drugs; Gastric cancer; Targeted therapy

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CEDIRANIB; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; LAPATINIB; MATUZUMAB; NIMOTUZUMAB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLACEBO; RAMUCIRUMAB; SONIC HEDGEHOG PROTEIN; SORAFENIB; SUNITINIB; TRASTUZUMAB;

ANEMIA; ANTIANGIOGENIC THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; FATIGUE; HEART INFARCTION; HUMAN; INJECTION SITE REACTION; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; STOMACH PERFORATION; THROMBOEMBOLISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84866759547     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/btt.s23917     Document Type: Review

References (70)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Sugano K. Gastric cancer: pathogenesis, screening and treatment. Gastrointest Endosc Clin N Am. 2008;18(3):513-522.
3. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006;24(18): 2903-2909.
4. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008;358(1):36-46.
5. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991-4997.
6. Power DG, Kelsen DP, Shah MA. Advanced gastric cancer - slow but steady progress. Cancer Treat Rev. 2010;36(5):384-392.
7. Okines AF, Reynolds AR, Cunningham D. Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist. 2011;16(6):844-858.
8. Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996;77(5):858-863.
9. Yoshikawa T, Tsuburaya A, Kobayashi O, et al. Plasma concentration of VEGF and bFGF in patients with gastric carcinoma. Cancer Lett. 2000;153(1-2):7-12.
10. Shah MA, Ramanathan RK, Ilson DH, et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2006;24(33):5201-5206.
11. Shah MA, Jhawer M, Ilson DH, et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol. 2011;29(7):868-874.
12. Enzinger P, Ryan D, Regan E, et al. Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. J Clin Oncol. 2008;26 Suppl 15:S4552.
13. El-Rayes BF, Zalupski M, Bekai-Saab T, et al. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol. 2010;21(10):1999-2004.
14. Cohenuram MK, Lacy J. FOLFOX6 and bevacizumab (FOLFOX6/B) for metastatic esophageal, gastroesophageal (GE) and gastric cancer (G) adenocarcinoma: a single institution's initial clinical experience. Proceedings of GI ASCO; 2008:74.
15. Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 20 2011;29(30):3968-3976.
16. Shah M, Kang Y, Ohtsu A, et al. Tumor and blood plasma biomarker analyses in the AVAGAST phase III randomized study of first-line bevacizumab + capecitabine/cisplatin in patients with advanced gastric cancer. Ann Oncol. 2010;21 Suppl 8:S176.
17. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010;28(5):780-787.
18. Kim C, Lee JL, Choi YH, et al. Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer. Invest New Drugs. 2012;30(1):306-315.
19. Sun W, Powell M, O'Dwyer PJ, et al. Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol. 2010;28(18): 2947-2951.
20. Bang YJ, Kang YK, Kang WK, et al. Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs. 2011;29(6)L1449-L1458.
21. Moehler M, Mueller A, Hartmann JT, et al. An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer. 2011; 47(10):1511-1520.
22. Satoh T, Yamada Y, Muro K, et al. Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. Cancer Chemother Pharmacol. 2012;69(2):439-446.
23. Maeda K, Chung YS, Takatsuka S, et al. Tumour angiogenesis and tumour cell proliferation as prognostic indicators in gastric carcinoma. Br J Cancer. 1995;72(2):319-323.
24. Jüttner S, Wissmann C, Jöns T, et al. Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol. 2006;24(2):228-240.
25. Ding S, Li C, Lin S, et al. Distinct roles of VEGF-A and VEGF-C in tumour metastasis of gastric carcinoma. Oncol Rep. 2007;17(2):369-375.
26. Lurje G, Leers JM, Pohl A, et al. Genetic variations in angiogenesis pathway genes predict tumor recurrence in localized adenocarcinoma of the esophagus. Ann Surg. 2010;251(5):857-864.
27. Ahn JB, Rha SY, Shin SJ, et al. Circulating endothelial progenitor cells (EPC) for tumor vasculogenesis in gastric cancer patients. Cancer Lett. 2010;288(1):124-132.
28. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28(13):2137-2143.
29. Shojaei F, Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resist Updat. 2008;11(6):219-230.
30. Azam F, Mehta S, Harris AL. Mechanisms of resistance to antiangiogenesis therapy. Eur J Cancer. 2010;46(8):1323-1332.
31. Eikesdal HP, Kalluri R. Drug resistance associated with antiangiogenesis therapy. Semin Cancer Biol. 2009;19(5):310-317.
32. Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther. 2008;7(12): 3670-3684.
33. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol. 2002;20(Suppl 18):S1-S13.
34. Okines A, Cunningham D, Chau I. Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol. 2011;8(8):492-503.
35. Cappetta A, Lonardi S, Pastorelli D, Bergamo F, Lombardi G, Zagonel V. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies. Crit Rev Oncol Hematol. 2012;81(1):38-48.
36. Enzinger PC, Burtness B, Hollis D, et al. CALGB 80403/ECOG 1206: a randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer. J Clin Oncol. 2010;28(Suppl 15):a4006.
37. Chan JA, Blaszkowsky LS, Enzinger PC, et al. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma. Ann Oncol. 2011;22(6):1367-1373.
38. Gold PJ, Goldman B, Iqbal S, et al. Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415). J Thorac Oncol. 2010;5(9):1472-1476.
39. Tebbutt NC, Sourjina T, Strickland AH, et al. ATTAX2: docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophago-gastric cancer-final results of a multicentre phase II trial by the AGITG. Proceedings of the GI ASCO; 2008:a87.
40. Stein A, Al-Batran SE, Arnold D, Peinert S, Siewczynski R, Schmoll HJ. Cetuximab with irinotecan as salvage therapy in heavily pretreated patients with metastatic gastric cancer. Proceedings of the GI ASCO; 2007:a47.
41. Rao S, Starling N, Cunningham D, et al. Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study. Ann Oncol. 2010;21(11):2213.2219.
42. Kim, YH, Sasaki Y, Lee KH. et al. Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5.fluorouracil.based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary results. J Clin Oncol. 2011;29(Suppl 4):a87.
43. Dragovich T, McCoy S, Fenoglio-Preiser CM, et al. Phase II trial of erlotinib in gastrooesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol. 2006;249(30):4922-4927.
44. Rojo F, Tabernero J, Albanell J, et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol. 2006;24(26):4309-4316.
45. Rodriguez CP, Adelstein DJ, Rice TW, et al. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol. 2010;5(2):229-235.
46. Fornaro L, Lucchesi M, Caparello C, et al. Anti-HER agents in gastric cancer: from bench to bedside. Nat Rev Gastroenterol Hepatol. 2011;8(7):369-383.
47. Meza-Junco J, Au HJ, Sawyer MB. Critical appraisal of trastuzumab in treatment of advanced stomach cancer. Cancer Manag Res. 2011;3: 57.64.
48. Bang Y, Chung H, Xu J, et al. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol. 2009;27(Suppl 15S):a4556.
49. Gong SJ, Jin CJ, Rha SY, Chung HC. Growth inhibitory effects of trastuzumab and chemotherapeutic drugs in gastric cancer cell lines. Cancer Lett. 2004;214(2):215-224.
50. Cortes-Funes H, Rivera F, Ales I, et al. Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification. J Clin Oncol. 2007; 25(Suppl 18):a4613.
51. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-697.
52. Iqbal S, Goldman B, Lenz HJ, Fenoglio-Preiser CM, Blanke CD. S0413: A phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer. J Clin Oncol. 2007;25(Suppl 18):a4621.
53. Hecht J, Urba SG, Koehler M, et al. Lapatinib monotherapy in recurrent upper gastrointestinal malignancy: phase II efficacy and biomarker analyses. The Proceedings of GI ASCO; 2008:a43.
54. Lenz H, Zhang W, Kemner AM. Lapatinib 1 capecitabine in advanced gastric cancer: An open-label phase II study of non ERBB2-targeted disease. Ann Oncol. 2010;21(Suppl 8):S817.
55. Roth A, Moehler MH, Mauer M, et al. Lapatinib in combination with ECF/X in EGFR1 or HER2-overexpressing first-line metastatic gastric cancer (GC): a phase II randomized placebo controlled trial (EORTC 40071). J Clin Oncol. 2010;28(Suppl 15):a205.
56. Satoh T, Bang Y, Wang J, et al. Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer. J Clin Oncol. 2010;28(Suppl 15): a4057.
57. ClinicalTrials.gov. LOGiC. Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib. Available at: http://clinicaltrials.gov/ct2/show/NCT00680901?term=LOGiC&rank=8.
58. Di Fiore F, Sesboue R, Michel P, Sabourin JC, Frebourg T. Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer. 2010;103(12):1765-1772.
59. Chen J, Huang XF, Katsifis A. Activation of signal pathways and the resistance to anti-EGFR treatment in colorectal cancer. J Cell Biochem. 2010;111(5):1082-1086.
60. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010;28(7): 1254-1261.
61. Pinto C, Di Fabio F, Siena S, et al. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol. 2007;18(3):510-517.
62. Stella G, Rojas Llimpe FL, Barone C, et al. KRAS and BRAF mutational status as response biomarkers to cetuximab combination therapy in advanced gastric cancer patients. J Clin Oncol. 2009;27(Suppl 15): a15503.
63. Wu WK, Tse TT, Sung JJ, Li ZJ, Yu L, Cho CH. Expression of ErbB receptors and their cognate ligands in gastric and colon cancer cell lines. Anticancer Res. 2009;29(1):229-234.
64. Takiuchi H, Doi T, Muro K, et al. Everolimus in patients with previously treated metastatic gastric cancer: Final results of a multicenter phase II study. The Proceedings of GI ASCO; 2010:a52.
65. Van Cutsem E, Yeh KH, Bang YJ, et al. Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1. J Clin Oncol. 2012;4(Suppl 30):LBA3.
66. Sierra JR, Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 2011;3(Suppl 1):S21-S35.
67. Christoph DC, Schuler M. Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies. Expert Rev Anticancer Ther. 2011;11(7):1115-1130.
68. Ii M, Li H, Adachi Y, et al. The efficacy of IGF-I receptor monoclonal antibody against human gastrointestinal carcinomas is independent of k-ras mutation status. Clin Cancer Res. 2011;17(15):5048-5059.
69. Sankhala KK, Mita MM, Mita AC, Takimoto CH. Heat shock proteins: a potential anticancer target. Curr Drug Targets. 2011;12(14): 2001-2008.
70. Marini KD, Payne BJ, Watkins DN, Martelotto LG. Mechanisms of Hedgehog signalling in cancer. Growth Factors. 2011;29(6): 221-234.